TOP2A and cancer: Since many TOP2 inhibitors, including those used in clinics (e.g., mitoxantrone and doxorubicin), are DNA intercalators that indirectly inhibit TOP2 activity, they will result in uncontrollable genotoxic and cytotoxic effects to not only cancer cells, but also benign cells.